European Archives - Page 500 of 1102 - European Medical Journal

Prediabetes: Challenges, Novel Solutions, and Future Directions

Prediabetes is a state of hyperglycaemia, impaired glucose tolerance, and is associated with weight loss often preceding Type 2 Diabetes…

Predictive Value of Malignancy Index for Tumour Staging

In this study, using transurethral and biopsy tissue and plasma samples, the robustness of a malignancy index that not only discriminates PCa from non–PCa but is also able to predict tumour stage is also examined.

Dermatophyte Monitoring in an Iranian Training Dermatology Hospital

Dermatophytes are the keratinophilic moulds living on the superficial layer of human and animal skin and are transmitted by direct and…

STRIDE II Podcast

This podcast is an exploration of the journey from publication to practice of The Selecting Therapeutic Targets in IBD initiative, known as STRIDE II.

Sniffing Around Surgical Research

Jonathan and David Jayne discuss global citizenship with the aim of gaining international experience and advancing clinical practice, and…

Higher Risk of Death with Processed Meat Consumption in Patients with Inflammatory Bowel Disease

Evidence linking frequent consumption of processed meat with higher risk of death in IBD patients has been reported…

Nerve Stimulation Study Shows Promise for Patients with Inflammatory Bowel Disease

A a safe and effective profile for nerve stimulation treatment in children and adults with mild-to-moderate IBD has been discovered…

Inter-organ Communication in Obesity: Adipose Tissue in Type 2 Diabetes

Gijs Goossens delves into inter-organ communication in obesity, with a focus on the role and importance of adipose tissue dysfunction in the development of type 2 diabetes. This session also explores the mechanisms involved in obesity-related insulin resistance, and the pressing need for phenotyping beyond current strategies to develop personalised interventions

EMJ Hepatology 10 [Supplement 1] 2022 Feature Image

EMJ Hepatology 10 [Supplement 1] 2022

This supplement reviews two posters presented at the ‘Liver Meeting®’ 2021. Both posters delved into new trial data on the efficacy of Aramchol™ to treat non-alcoholic steatohepatitis, analysing biopsy outcomes, fibrosis improvement, and biomarker data.

EMJ Hepatology 10 [Supplement 1] 2022 Feature Image

New Data on Aramchol™: Efficacy of a Higher Daily Exposure to Aramchol on Fibrosis Improvement in the ARMOR Study Open-Label Part

Non-alcoholic steatohepatitis (NASH) is the advanced form of non-alcoholic fatty liver disease, which can lead to further…